Virus-Like Particles as Carriers for T-Cell Epitopes: Limited Inhibition of T-Cell Priming by Carrier-Specific Antibodies

ABSTRACT Virus-like particles (VLPs) are able to induce cytotoxic T-cell responses in the absence of infection or replication. This makes VLPs promising candidates for the development of recombinant vaccines. However, VLPs are also potent inducers of B-cell responses, and it is generally assumed that such VLP-specific antibodies interfere with the induction of protective immune responses, a phenomenon summarized as carrier suppression. In this study, we investigated the impact of preexisting VLP-specific antibodies on the induction of specific cytotoxic T-cell and Th-cell responses in mice. The data show that VLP-specific antibodies did not measurably reduce antigen presentation in vitro or in vivo. Nevertheless, T-cell priming was slightly reduced by antigen-specific antibodies; however, the overall reduction was limited and vaccination with VLPs in the presence of VLP-specific antibodies still resulted in protective T-cell responses. Thus, carrier suppression is unlikely to be a limiting factor for VLP-based T-cell vaccines.

[1]  T. Storni,et al.  Loading of MHC Class I and II Presentation Pathways by Exogenous Antigens: A Quantitative In Vivo Comparison , 2004, The Journal of Immunology.

[2]  K. Schwarz,et al.  Nonmethylated CG Motifs Packaged into Virus-Like Particles Induce Protective Cytotoxic T Cell Responses in the Absence of Systemic Side Effects , 2004, The Journal of Immunology.

[3]  T. Storni,et al.  Innate Immunity Together with Duration of Antigen Persistence Regulate Effector T Cell Induction , 2003, The Journal of Immunology.

[4]  M. Bevan,et al.  Constitutive versus Activation-dependent Cross-Presentation of Immune Complexes by CD8+ and CD8− Dendritic Cells In Vivo , 2002, The Journal of experimental medicine.

[5]  R. Zinkernagel On cross‐priming of MHC class I‐specific CTL: rule or exception? , 2002, European journal of immunology.

[6]  J. Ravetch,et al.  Inducing Tumor Immunity through the Selective Engagement of Activating Fcγ Receptors on Dendritic Cells , 2002, The Journal of experimental medicine.

[7]  A. Jegerlehner,et al.  Critical Role for Activation of Antigen-Presenting Cells in Priming of Cytotoxic T Cell Responses After Vaccination with Virus-Like Particles1 , 2002, The Journal of Immunology.

[8]  F. Lechner,et al.  Cross‐presentation of virus‐like particles by skin‐derived CD8– dendritic cells: a dispensable role for TAP , 2002, European journal of immunology.

[9]  J. Schiller,et al.  Effect of preexisting neutralizing antibodies on the anti-tumor immune response induced by chimeric human papillomavirus virus-like particle vaccines. , 2001, Virology.

[10]  P. Pumpens,et al.  HBV Core Particles as a Carrier for B Cell/T Cell Epitopes , 2001, Intervirology.

[11]  C. Siegrist Neonatal and early life vaccinology. , 2001, Vaccine.

[12]  P. Lenz,et al.  Papillomavirus-Like Particles Induce Acute Activation of Dendritic Cells1 , 2001, The Journal of Immunology.

[13]  P. Wallace,et al.  Exogenous antigen targeted to FcgammaRI on myeloid cells is presented in association with MHC class I. , 2001, Journal of immunological methods.

[14]  M. Bevan,et al.  Cd8+ but Not Cd8− Dendritic Cells Cross-Prime Cytotoxic T Cells in Vivo , 2000, The Journal of experimental medicine.

[15]  M. Bachmann,et al.  CD8+ T Cells Mediate CD40-independent Maturation of Dendritic Cells In Vivo , 1999, The Journal of experimental medicine.

[16]  A. Benner,et al.  Immune response to human papillomavirus 16 L1E7 chimeric virus‐like particles: Induction of cytotoxic T cells and specific tumor protection , 1999, International journal of cancer.

[17]  P. Ricciardi-Castagnoli,et al.  Fcγ Receptor–mediated Induction of Dendritic Cell Maturation and Major Histocompatibility Complex Class I–restricted Antigen Presentation after Immune Complex Internalization , 1999, The Journal of experimental medicine.

[18]  P. Lambert,et al.  Influence of maternal antibodies on vaccine responses: inhibition of antibody but not T cell responses allows successful early prime‐boost strategies in mice , 1998, European journal of immunology.

[19]  S Oehen,et al.  Differentiation of naive CTL to effector and memory CTL: correlation of effector function with phenotype and cell division. , 1998, Journal of immunology.

[20]  R. Zinkernagel,et al.  Virus‐specific major MHC class II‐restricted TCR‐transgenic mice: effects on humoral and cellular immune responses after viral infection , 1998, European journal of immunology.

[21]  P. Ricciardi-Castagnoli,et al.  Dendritic cells process exogenous viral proteins and virus‐like particles for class I presentation to CD8+ cytotoxic T lymphocytes , 1996, European journal of immunology.

[22]  J. Reimann,et al.  MHC class I-restricted CTL responses to exogenous antigens. , 1996, Immunity.

[23]  S. Tonegawa,et al.  Presentation of endogenous viral proteins in association with major histocompatibility complex class II: On the role of intracellular compartmentalization, invariant chain and the TAP transporter system , 1995, European journal of immunology.

[24]  C Danieli,et al.  Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products , 1995, The Journal of experimental medicine.

[25]  R. Zinkernagel,et al.  Immunogenicity of a viral model vaccine after different inactivation procedures , 1994, Medical Microbiology and Immunology.

[26]  R. Zinkernagel,et al.  Formalin inactivation of vesicular stomatitis virus impairs T-cell- but not T-help-independent B-cell responses , 1993, Journal of virology.

[27]  R M Zinkernagel,et al.  Quantification of lymphocytic choriomeningitis virus with an immunological focus assay in 24- or 96-well plates. , 1991, Journal of virological methods.

[28]  A. Trzeciak,et al.  Use of prior vaccinations for the development of new vaccines. , 1990, Science.

[29]  H. Pircher,et al.  Tolerance induction in double specific T-cell receptor transgenic mice varies with antigen , 1989, Nature.

[30]  A. Lanzavecchia Antigen Uptake and Accumulation in Antigen‐Specific B Cells , 1987, Immunological reviews.

[31]  M. Gething,et al.  Antigen Presentation Pathways to Class I and Class II MHC‐Restricted T Lymphocytes , 1987, Immunological reviews.

[32]  C. Bangham Passively acquired antibodies to respiratory syncytial virus impair the secondary cytotoxic T-cell response in the neonatal mouse. , 1986, Immunology.

[33]  R. Germain Immunology: The ins and outs of antigen processing and presentations , 1986, Nature.

[34]  T. Braciale,et al.  Differences in antigen presentation to MHC class I-and class II- restricted influenza virus-specific cytolytic T lymphocyte clones , 1986, The Journal of experimental medicine.

[35]  F. Ennis,et al.  Persistence of maternal antibody in infants beyond 12 months: mechanism of measles vaccine failure. , 1977, The Journal of pediatrics.

[36]  F. Perkins,et al.  A Comparison of the Responses of 100 Infants to Primary Poliomyelitis Immunization with Two and with Three Doses of Vaccine , 1959, British medical journal.

[37]  A. Lanzavecchia,et al.  Mannose receptor mediated antigen uptake and presentation in human dendritic cells. , 1997, Advances in experimental medicine and biology.